Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma

被引:49
|
作者
Krieger, D. A. [1 ]
Hudgins, P. A. [2 ]
Nayak, G. K. [7 ]
Baugnon, K. L. [2 ]
Corey, A. S. [2 ]
Patel, M. R. [3 ]
Beitler, J. J. [3 ,4 ,5 ]
Saba, N. F. [5 ]
Liu, Y. [6 ]
Aiken, A. H. [2 ]
机构
[1] Hackensack Univ Med Ctr, Dept Radiol, Hackensack, NJ USA
[2] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA USA
[3] Emory Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Atlanta, GA USA
[4] Emory Univ, Sch Med, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA USA
[5] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[6] Emory Univ, Sch Med, Dept Biostat, Winship Canc Inst, Atlanta, GA USA
[7] NYU, Dept Radiol, Sch Med, 560 1st Ave, New York, NY 10016 USA
关键词
SURVEILLANCE PET/CT; CANCER; UTILITY;
D O I
10.3174/ajnr.A5157
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: The Head and Neck Imaging Reporting and Data System (NI-RADS) surveillance template for head and neck cancer includes a numeric assessment of suspicion for recurrence (1-4) for the primary site and neck. Category 1 indicates no evidence of recurrence; category 2, low suspicion of recurrence; category 3, high suspicion of recurrence; and category 4, known recurrence. Our purpose was to evaluate the performance of the NI-RADS scoring system to predict local and regional disease recurrence or persistence. MATERIALS AND METHODS: This study was classified as a quality-improvement project by the institutional review board. A retrospective database search yielded 500 consecutive cases interpreted using the NI-RADS template. Cases without a numeric score, non-squamous cell carcinoma primary tumors, and primary squamous cell carcinoma outside the head and neck were excluded. The electronic medical record was reviewed to determine the subsequent management, pathology results, and outcome of clinical and radiologic follow-up. RESULTS: A total of 318 scans and 618 targets (314 primary targets and 304 nodal targets) met the inclusion criteria. Among the 618 targets, 85.4% were scored NI-RADS 1; 9.4% were scored NI-RADS 2; and 5.2% were scored NI-RADS 3. The rates of positive disease were 3.79%, 17.2%, and 59.4% for each NI-RADS category, respectively. Univariate association analysis demonstrated a strong association between the NI-RADS score and ultimate disease recurrence, with P < .001 for primary and regional sites. CONCLUSIONS: The baseline performance of NI-RADS was good, demonstrating significant discrimination among the categories 1-3 for predicting disease.
引用
收藏
页码:1193 / 1199
页数:7
相关论文
共 50 条
  • [41] Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck
    Nadler, Eric
    Joo, Seongjung
    Boyd, Marley
    Black-Shinn, Jenny
    Chirovsky, Diana
    FUTURE ONCOLOGY, 2019, 15 (07) : 739 - 752
  • [42] Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma
    Cho, Hironori
    Nishiike, Suetaka
    Yamamoto, Yoshifumi
    Takenaka, Yukinori
    Nakahara, Susumu
    Yasui, Toshimichi
    Hanamoto, Atsushi
    Inohara, Hidenori
    AURIS NASUS LARYNX, 2015, 42 (05) : 396 - 400
  • [43] Salvage chemotherapy after progression on immunotherapy in recurrent/metastatic squamous cell head and neck carcinoma
    Llop, Sandra
    Plana, Maria
    Tous, Sara
    Ferrando-Diez, Angelica
    Brenes, Jesus
    Juarez, Marc
    Vidales, Zara
    Vilajosana, Esther
    Linares, Isabel
    Arribas, Lorena
    Duch, Maria
    Fulla, Marta
    Brunet, Aina
    Lozano, Alicia
    Cirauqui, Beatriz
    Mesia, Ricard
    Oliva, Marc
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [44] Reirradiation with Alternating Docetaxel-Based Chemotherapy for Recurrent Head and Neck Squamous Cell Carcinoma
    Berger, Bernhard
    Belka, Claus
    Weinmann, Martin
    Bamberg, Michael
    Budach, Wilfried
    Hehr, Thomas
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 (05) : 255 - 261
  • [45] Salvage surgery for head and neck squamous cell carcinoma
    Mandapathil, Magis
    Roessler, Marion
    Werner, Jochen A.
    Silver, Carl E.
    Rinaldo, Alessandra
    Ferlito, Alfio
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2014, 271 (07) : 1845 - 1850
  • [46] Combination treatment of arsenic trioxide and osimertinib in recurrent and metastatic head and neck squamous cell carcinoma
    Hsieh, Ching-Yun
    Chang, Wei-Chao
    Lin, Ching-Chan
    Chen, Jong-Hang
    Lin, Chen-Yuan
    Liu, Chia-Hua
    Lin, Chen
    Hung, Mien-Chie
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (11): : 5049 - +
  • [47] Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck
    Shetty, Aditya V.
    Wong, Deborah J.
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2017, 50 (04) : 775 - +
  • [48] Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma
    Almokadem, Salah
    CURRENT MOLECULAR PHARMACOLOGY, 2016, 9 (03) : 226 - 230
  • [49] Preclinical models in head and neck squamous cell carcinoma
    Chaves, Patricia
    Garrido, Maria
    Oliver, Javier
    Perez-Ruiz, Elisabeth
    Barragan, Isabel
    Rueda-Dominguez, Antonio
    BRITISH JOURNAL OF CANCER, 2023, 128 (10) : 1819 - 1827
  • [50] Mouse Models for Head and Neck Squamous Cell Carcinoma
    Zhou, J.
    Liu, C.
    Amornphimoltham, P.
    Cheong, S. C.
    Gutkind, J. S.
    Chen, Q.
    Wang, Z.
    JOURNAL OF DENTAL RESEARCH, 2024, 103 (06) : 585 - 595